Mind the gap
Schuller, Y.

Citation for published version (APA):
Schuller, Y. (2018). Mind the gap: Bridging the difference between efficacy and effectiveness of orphan drugs

General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: http://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
Mind the Gap

Bridging the difference between efficacy and effectiveness of orphan drugs

Yvonne Schuller
Mind the gap
Bridging the difference between efficacy and effectiveness of orphan drugs

Y. Schuller
Mind the gap

Bridging the difference between efficacy and effectiveness of orphan drugs

ACADEMISCH PROEFSCHRIFT
ter verkrijging van de graad van doctor
aan de Universiteit van Amsterdam
op gezag van de Rector Magnificus
prof. dr. ir. K.I.J. Maex
ten overstaan van een door het College voor Promoties ingestelde commissie,
in het openbaar te verdedigen in de Agnietenkapel
op woensdag 4 juli 2018, te 10.00 uur
door Yvonne Schuller
geboren te Beverwijk

Colofon

© 2018, Yvonne Schuller, Amsterdam, The Netherlands

All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by any means, without permission of the author.

Work in this thesis was supported by the Dutch Medicines Evaluation Board (College ter Beoordeling van Geneesmiddelen).

Financial support for the printing of this thesis was kindly provided by AMC Medical Research, de Gaucher Stichting, Dutch Medicines Evaluation Board and ChipSoft.

Author Yvonne Schuller
Lay-out Ilse Stronks, persoonlijkproefschrift.nl
Cover Evelien Jagtman, www.evelienjagtman.com
Printing Ipskamp Printing
Promotiecommissie

Promotor
Prof. dr. C.E.M. Hollak  AMC - UvA

Copromotores
Dr. M. Biegstraaten  AMC - UvA
Dr. V.V. Stoyanova-Beninska  CBG-MEB

Overige leden
Prof. dr. B.M. Nogueira Sepodes  University of Lisbon
Prof. dr. D. Cassiman  UZ Leuven
Prof. dr. J.H.M. Schellens  Antoni van Leeuwenhoek ziekenhuis
Dr. R.P. Hagendijk  Universiteit van Amsterdam
Prof. dr. M.G.W. Dijkgraaf  AMC - UvA
Prof. dr. M.J. Kersten  AMC - UvA

Faculteit der Geneeskunde

Contents

Chapter 1  General introduction  7
Chapter 2  The quality of economic evaluations of ultra-orphan drugs in Europe – a systematic review.  17
Chapter 3  Factors contributing to the efficacy-effectiveness gap in the case of orphan drugs for metabolic diseases.  39
Chapter 4  Dose-finding studies among orphan drugs approved in the EU – a retrospective analysis.  81
Chapter 5  Hurdles in access to high-priced orphan drugs.  113
Chapter 6  Adaptive pathway development for Fabry disease: a clinical approach.  143
Chapter 7  Oncologic orphan drugs approved in the EU – Do clinical trial data correspond with real-world effectiveness?  159
Chapter 8  Clinical benefit of systemic treatment in patients with advanced pancreatic and gastro-intestinal neuroendocrine tumors according to ESMO-MCBS and ASCO framework.  193
Chapter 9  General discussion and future perspectives  217
Chapter 10  Addendum
  Summary  233
  Nederlandse Samenvatting  238
  List of co-authors and affiliations  243
  List of publications  245
  List of acronyms and abbreviations  246
  PhD Portfolio  249
  About the author  251
  Acknowledgements/Dankwoord  252